National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus

TThe annual increase in the prevalence of type 2 diabetes mellitus emphasizes the relevance of the search for new treatment options, along with necessity for regular review of proven therapeutic solutions. Today, dipeptidyl peptidase-4 inhibitors (DPP-4i, gliptins) are effective and safe hypoglycemic therapy, which is included in modern standards of treatment of type 2 diabetes. In 2022, the availability of this group of drugs for Russian patients has significantly increased. This circumstance became a prerequisite for holding a National Council of Experts with the participation of members of the Russian Association of Endocrinologists. The task of the Council was to determine the place of DPP-4i in the treatment of patients with type 2 diabetes in 2023. During the meeting of the Council, experts summarized the evidence base of DPP-4i taking into account the latest scientific data and determined the optimal clinical portraits of patients for the use of DPP-4i in accordance with updated national recommendations.

1. Dedov I, Shestakova M, Benedetti MM, Simon D, Pakhomov I, Galstyan G. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res Clin Pract. 2016;115:90-95. doi:10.1016/j.diabres.2016.02.010

2. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Sazonova D.V., Mokrysheva N.G. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes mellitus. 2023;26(2):104-123. (In Russ.) doi: https://doi.org/10.14341/DM13035

3. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564-2571. doi:10.1007/s00125-006-0416-z

4. Zhan M, Xu T, Wu F, Tang Y. Sitagliptin in the treatment of type 2 diabetes: a meta-analysis. J Evid Based Med. 2012;5(3):154-165. doi:10.1111/j.1756-5391.2012.01189.x

5. Ku EJ, Jung KY, Kim YJ, et al. Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study. PLoS One. 2015;10(6):e0129477. Published 2015 Jun 12. doi:10.1371/journal.pone.0129477

6. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes [published correction appears in N Engl J Med. 2015 Aug 6;373(6):586]. N Engl J Med. 2015;373(3):232-242. doi:10.1056/NEJMoa1501352

7. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326. doi:10.1056/NEJMoa1307684

8. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-1335. doi:10.1056/NEJMoa1305889

9. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79. doi:10.1001/jama.2018.18269

10. Mathieu C, Barnett AH, Brath H, et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract. 2013;67(10):947-956. doi:10.1111/ijcp.12252

11. McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab. 2015;17(11):1085-1092. doi:10.1111/dom.12548

12. Merck Sharp & Dohme Ltd. Januvia – Summary of Product Characteristics. July 2013

13. Bristol-Myers Squibb/AstraZeneca EEIG. Onglyza – Summary of Product Characteristics. July 2013

14. Novartis Europharm Ltd. Galvus – Summary of Product Characteristics. July 2013

15. Boehringer Ingelheim International GmbH. Trajenta – Summary of Product Characteristics. August 2013

16. American Diabetes Association. 7. Approaches to Glycemic Treatment. Diabetes Care. 2016;39 Suppl 1:S52-S59. doi:10.2337/dc16-S010

17. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206. doi:10.1001/jama.298.2.194;

18. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology. 2010;86(1):44-57. doi:10.1159/000314690

19. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2014;74(5):587-610. doi:10.1007/s40265-014-0199-3

20. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008;2008(2):CD006739. Published 2008 Apr 16. doi:10.1002/14651858.CD006739.pub2

21. Data of the Federal Register of Diabetes Mellitus of the Moscow Region [date of access: 01/09/2023] (In Russ.)]

22. Dedov I.I. et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition. Diabetes mellitus. 2021;24(1S):1-148. (In Russ.) doi: https://doi.org/10.14341/DM12802

23. Matthews DR, Paldánius PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519-1529. doi:10.1016/S0140-6736(19)32131-2

24. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th edition. M.; 2023 doi: https://doi.org/10.14341/DM13042

25. Shestakova E.A. Second line therapy in type 2 diabetes: legacy effect activation. Diabetes mellitus. 2017;20(5):356-362. (In Russ.) doi:10.14341/DM8793

26. Derosa G, D'Angelo A, Maffioli P. Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. Pharmacol Res. 2015;100:127-134. doi:10.1016/j.phrs.2015.07.019

27. Dudinskaya E.N., Tkacheva O.N. Functional status of an elderly patient with diabetes. Consilium Medicum. 2020; 22 (4): 31–35. doi: 10.26442/20751753.2020.4.200156

28. Geriatrics. National Guide / R. I. Absalyamov, E. A. Andreeva, A. N. Barinova [et al.]. – 2nd edition, revised and supplemented. – Moscow : GEOTAR-Media Publishing Group LLC, 2023. – 720 p. – (National Guidelines) doi 10.33029/9704-7109-8GNR-2023-1-720.

29. Moheet A, Mangia S, Seaquist ER. Impact of diabetes on cognitive function and brain structure. Ann N Y Acad Sci. 2015;1353:60-71. doi:10.1111/nyas.12807

30. Schott G, Martinez YV, Ediriweera de Silva RE, et al. Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing. BMC Geriatr. 2017;17(Suppl 1):226. Published 2017 Oct 16. doi:10.1186/s12877-017-0571-8

31. Boccardi V, Mecocci P. DPP-4 inhibitors: meeting the needs of the very old population. Acta Diabetol. 2019;56(7):819. doi:10.1007/s00592-019-01329-2

32. Nagao M, Sasaki J, Sugihara H, et al. Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study. Sci Rep. 2023;13(1):134. Published 2023 Jan 4. doi:10.1038/s41598-022-27301-9

33. Brailova N.V., Dudinskaya E.N., Tkacheva O.N., Sharashkina N.V., Strazhesco I.D., Akasheva D.U., Shestakova M.V. Relationship between telomerase activity and parameters of carbohydrate metabolism and vascular wall. Cardiovascular Therapy and Prevention. 2019;18(6):33-39. (In Russ.) doi:10.15829/1728-8800-2019-2233

34. Kang SM, Park JH. Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control. Clin Med Insights Endocrinol Diabetes. 2021;14:11795514211051698. Published 2021 Oct 28. doi:10.1177/11795514211051698

35. Antoniou S, Naka KK, Papadakis M, et al. Effect of glycemic control on markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus: A review. World J Diabetes. 2021;12(11):1856-1874. doi:10.4239/wjd.v12.i11.1856